{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:56:06Z","timestamp":1785434166252,"version":"3.56.0"},"reference-count":18,"publisher":"Universidad Nacional de C\u00f3rdoba","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Fac Cien Med Univ Nac Cordoba"],"abstract":"<jats:p>Objetivo: Describir los resultados cl\u00ednicos del uso de tofacitinib gen\u00e9rico en pacientes con artritis reumatoidea (AR) que lo iniciaron de novo o realizaron un cambio no m\u00e9dico desde la formulaci\u00f3n original. M\u00e9todos: Cohorte retrospectiva de adultos con AR que iniciaron tofacitinib gen\u00e9rico (JANVAX\u00ae) o cambiaron desde tofacitinib original (XELJANZ\u00ae). Se siguieron hasta la interrupci\u00f3n del tratamiento, fallecimiento, o fin de seguimiento (12 meses). La eficacia se evalu\u00f3 con la escala DAS28-ESR utilizando un modelos de efectos mixtos. El grupo de cambio fue evaluado a 0, 6 y 12 meses; el grupo de inicio a los 0, 3, 6 y 12 meses. La seguridad fue evaluada por eventos adversos. Resultados: Se incluyeron 42 pacientes con AR (24 de cambio y 18 de inicio). Nueve pacientes interrumpieron el tratamiento. En el grupo de cambio, el DAS28-ESR se mantuvo estable (2,96; 3,08; 3,10; p = 0,70). En el de inicio, mejor\u00f3 significativamente (5,3; 3,42; 3,49; 3,31; p &lt; 0,001). No se informaron eventos cardiovasculares mayores (MACE). Se registr\u00f3 un fallecimiento de causa no identificada, tres infecciones graves, un tromboembolismo pulmonar y un diagn\u00f3stico de neoplasia maligna durante el seguimiento.\u00a0Conclusiones: El cambio no m\u00e9dico a tofacitinib gen\u00e9rico y el inicio de tratamiento se asociaron con buena respuesta cl\u00ednica en t\u00e9rminos de efectividad y sin evidencia de nuevos problemas de seguridad. Sin embargo, el tama\u00f1o muestral limitado requiere de estudios adicionales para confirmar estos resultados.<\/jats:p>","DOI":"10.31053\/1853.0605.v83.n1.49067","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:03:36Z","timestamp":1774890216000},"page":"e49067","source":"Crossref","is-referenced-by-count":0,"title":["Evidencia del mundo real sobre el uso de tofacitinib gen\u00e9rico en pacientes con artritis reumatoidea"],"prefix":"10.31053","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1844-6863","authenticated-orcid":false,"given":"Luis Angel","family":"Di Giuseppe","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6161-9147","authenticated-orcid":false,"given":"Mariana Andrea","family":"Burgos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-7069","authenticated-orcid":false,"given":"Maria Lourdes","family":"Posadas Mart\u00ednez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Lieber","family":"Vargas Casalles","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9269-5592","authenticated-orcid":false,"given":"Karina Elena","family":"Alvarez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1039-1032","authenticated-orcid":false,"given":"Gabriela","family":"Buela","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5479-143X","authenticated-orcid":false,"given":"Maria Celeste","family":"Puga","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique Roberto","family":"Soriano Guppy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-0761","authenticated-orcid":false,"given":"Javier Eduardo","family":"Rosa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00bq4rw46","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Italiano de Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"12333","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Rosa JE, Garc\u00eda MV, Luissi A, Pierini F, Sabelli M, Mollerach F, Soriano ER. Rheumatoid Arthritis Patient's Journey: Delay in Diagnosis and Treatment. J Clin Rheumatol. 2020 Oct;26(7S Suppl 2):S148-S152. doi: 10.1097\/RHU.0000000000001196. DOI: 10.1097\/RHU.0000000000001196","DOI":"10.1097\/RHU.0000000000001196"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis. 2016 Aug;75(8):1479-85. doi: 10.1136\/annrheumdis-2015-208324. DOI: 10.1136\/annrheumdis-2015-208324","DOI":"10.1136\/annrheumdis-2015-208324"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Comp\u00e1n MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, \u00d6st\u00f6r A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136\/annrheumdis-2015-207524. DOI: 10.1136\/annrheumdis-2015-207524","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. 4. Syngle D, Verma I, Chauhan K, Patyal S, Syngle A. AB0510 cost-effective analysis of generic targeted synthetic disease-modifying anti-rheumatic drug - tofacitinib in rheumatoid arthritis (Tira Cea Study). Ann Rheum Dis. 2023 Jun 1; 82(Suppl 1):1449-1449. doi: 10.1136\/annrheumdis-2023-eular.5306. DOI: 10.1136\/annrheumdis-2023-eular.5306","DOI":"10.1136\/annrheumdis-2023-eular.5306"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Phatak S, Khenat A, Malandkar M, Amin S. Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India. Clin Rheumatol. 2022 Oct;41(10):2961-2966. doi: 10.1007\/s10067-022-06205-z. DOI: 10.1007\/s10067-022-06205-z","DOI":"10.1007\/s10067-022-06205-z"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. 6. Zhao J, Huang H, Zhang Z. AB0509 clinical equivalence of generic and branded tofacitinib in real-world: a prospective longitudinal cohort study in rheumatoid arthritis patients. Ann Rheum Dis. 2023 Jun 1; 82(Suppl 1):1449-1449. doi: 10.1136\/annrheumdis-2023-eular.2267. DOI: 10.1136\/annrheumdis-2023-eular.2267","DOI":"10.1136\/annrheumdis-2023-eular.2267"},{"key":"ref6","unstructured":"7. Ministerio de Salud de la Naci\u00f3n (AR). Listado de IFAs con obligatoriedad de realizar: Estudios de BD\/BE con la normativa vigente. Buenos Aires: Ministerio de Salud de la Naci\u00f3n; 2024 [citado 2025 Jan 27]. Disponible en: https:\/\/www.argentina.gob.ar\/sites\/default\/files\/anmat_listado_de_ifas_con_obligatoriedad_de_realizar_marzo_2024.pdf."},{"key":"ref7","unstructured":"8. Donato M, Tortosa F, Montero G, Manoukian DE, Iglesias A, Meschini MJ, Marin GH. Definici\u00f3n de medicamento de alto precio y muy alto precio para Argentina. Medicina (B Aires). Medicina (B Aires). 2025;85(2):261-2802. Disponible en: https:\/\/www.medicinabuenosaires.com\/PMID\/40198162.pdf"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Dolinar R, Kohn CG, Lavernia F, Nguyen E. The non-medical switching of prescription medications. Postgrad Med. 2019; 131(5):335-341. doi:10.1080\/00325481.2019.1618195. DOI: 10.1080\/00325481.2019.1618195","DOI":"10.1080\/00325481.2019.1618195"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, Coleman CI. Communication of Medication Nonmedical Switching Policies and Procedures by Insurance Companies: Results of an E-Survey. Clin Ther. 2020 Jun;42(6):1077-1086. doi: 10.1016\/j.clinthera.2020.04.007. DOI: 10.1016\/j.clinthera.2020.04.007","DOI":"10.1016\/j.clinthera.2020.04.007"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9. doi: 10.1093\/rheumatology\/kes279. DOI: 10.1093\/rheumatology\/kes279","DOI":"10.1093\/rheumatology\/kes279"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016\/j.jbi.2019.103208. DOI: 10.1016\/j.jbi.2019.103208","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009 Jun;68(6):954-60. doi: 10.1136\/ard.2007.084459. DOI: 10.1136\/ard.2007.084459","DOI":"10.1136\/ard.2007.084459"},{"key":"ref13","unstructured":"14. Papale MR, Schiaffino S, Garc\u00eda Darderes DG. Manual de buenas pr\u00e1cticas de farmacovigilancia. Edici\u00f3n Latinoam\u00e9rica. Buenos Aires: Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Disponible en: https:\/\/www.argentina.gob.ar\/sites\/default\/files\/manual_de_fvg_edicion_latam.pdf"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Bilgin E, Ceylan F, Duran E, Fariso\u011fullari B, B\u00f6lek E\u00c7, Yardimci GK, Kili\u00e7 L, Akdo\u011fan A, Karada\u011f \u00d6, Apra\u015f Bilgen \u015e\u015e, Kiraz S, Ertenli A\u0130, Kalyoncu U. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turk J Med Sci. 2021 Feb 26;51(1):297-308. doi: 10.3906\/sag-2007-123. DOI: 10.3906\/sag-2007-123","DOI":"10.3906\/sag-2007-123"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Movahedi M, Choquette D, Coupal L, Cesta A, Li X, Keystone EC, Bombardier C, Investigators O. Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. BMJ Open. 2023 Mar 6;13(3):e063198. doi: 10.1136\/bmjopen-2022-063198. DOI: 10.1136\/bmjopen-2022-063198","DOI":"10.1136\/bmjopen-2022-063198"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Sugawara M, Fujieda Y, Noguchi A, Tanimura S, Shimizu Y, Nakagawa I, Yoshimura M, Abe N, Kono M, Kato M, Oku K, Amengual O, Yokota I, Takahashi H, Atsumi T. Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis. Clin Exp Rheumatol. 2022 Sep;40(9):1674-1680. doi: 10.55563\/clinexprheumatol\/czhc93. DOI: 10.55563\/clinexprheumatol\/czhc93","DOI":"10.55563\/clinexprheumatol\/czhc93"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Rovira Forns J. Drug prices: how are they established and what are their control mechanisms? Salud Colect. 2015; 11(1):35-48. DOI: 10.18294\/sc.2015.414","DOI":"10.18294\/sc.2015.414"}],"container-title":["Revista de la Facultad de Ciencias M\u00e9dicas de C\u00f3rdoba"],"original-title":[],"link":[{"URL":"http:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/download\/49067\/52557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/download\/49067\/52558","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/download\/49067\/52557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:07:58Z","timestamp":1775480878000},"score":1,"resource":{"primary":{"URL":"http:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/view\/49067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.31053\/1853.0605.v83.n1.49067","relation":{},"ISSN":["0014-6722","1853-0605"],"issn-type":[{"value":"0014-6722","type":"print"},{"value":"1853-0605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}